| ||Audit Committee||Compensation Committee||Nominating and Corporate Governance Committee|
Former CEO of Nodality, Inc.
Ms. Brege served as executive vice president, corporate affairs for Onyx Pharmaceuticals until December 2011. In this role, Ms. Brege was responsible for the oversight of all external relationships including medical and scientific affairs, government affairs and public affairs.
Previously, Ms. Brege held the roles of chief operating officer and executive vice president and chief business officer for Onyx. In these roles, she oversaw the expansion of key corporate capabilities and...
|Yvonne Greenstreet, MBChB, MBA |
|Yvonne Greenstreet, MBChB, MBA|
Former Senior Vice President and Head of Medicines Development at Pfizer
|Paul Hastings, Lead Director |
|Paul Hastings, Lead Director|
Mr. Hastings has served as president and chief executive officer of OncoMed Pharmaceuticals since January 2006. Prior to joining OncoMed, Mr. Hastings was president and chief executive officer of QLT, Inc. Before this role, Mr. Hastings served as president and chief executive officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. Prior to Axys, Mr. Hastings was president of Chiron Biopharmaceuticals and also held a variety of management positions of increasing respons...
|Mark Kronenfeld, MD |
|Mark Kronenfeld, MD|
Maimonides Medical Center
|John P. Longenecker, PhD |
|John P. Longenecker, PhD|
John P. Longenecker, Ph.D. currently serves as president, CEO and Director of HemaQuest Pharmaceuticals, a private biotechnology developing treatment for hemoglobinopathies including sickle cell disease and beta thalassemia. Dr Longenecker has 30 years’ experience in the biotech/pharmaceutical industry including the startup and growth of multiple biotechnology companies. He has led efforts in all aspects of company development from startup venture capital funding, initial and sec...
|Andreas Wicki, PhD |
|Andreas Wicki, PhD|
HBM Partners AG
Dr. Wicki is CEO of HBM Partners AG and HBM BioVentures AG, Europe’s largest private equity focused investment company dedicated to life sciences. Prior to this, from 1990-1998, he was co-owner and CEO of ANAWA Laboratorien AG and Clinserve AG, two life sciences CRO companies which he then sold to MDS Inc., a major life sciences services and clinical research organization. After the acquisition, from 1998-2001, he was Senior Vice President of the European Analytical Operations at MDS I...
|| || |